Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that Ordinary Shares (“Shares”) and American Depositary Shares (“ADSs”) of the Company, as set out below, have been acquired today for the Non-Executive Directors, being the part of their total fees that are paid in shares for the period of service from January 1 to March 31, 2015.
|Type of Security (1)||Number of Shares/ADSs|
|Dr. Steven Gillis||ADSs||41|
|Dr. David Ginsburg||ADSs||35|
(1) One ADS is equal to three Shares
The Shares and ADSs were acquired on the London Stock Exchange and NASDAQ respectively at £54.3489 per Share and $237.20 per ADS.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Deputy Company Secretary
+44 1256 894157
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
Click here for the PDF version of this press release.